|Slideshows|October 29, 2022

Scariest in Psychiatry

What scares mental health clinicians? We asked, and these brave individuals replied…

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Related Content

Happy Halloween! To celebrate, Psychiatric Times® is looking back at our Scariest in Psychiatry series, which highlights clinicians’ most frightening, worrisome, and concerning issues in psychiatry.

What Scares Mental Health Clinicians?

ByErin O'Brien

October 31st 2023

Sorro Encounters Some of the Scariest Topics in the House of Psychiatry

ByH. Steven Moffic, MD

October 31st 2022

A Story of Crisis Negotiation

ByScott W. Allen, PhD, ABPP

October 27th 2022

Prior Authorizations and (Micro)managed Care

BySara Robinson, DNP, RN, PMHNP-BC

October 24th 2022

The Negative Impact of the Biodiversity Threat on Mental Health

ByTaish Malone, PhD, LPC-S

October 20th 2022

Latest CME

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Scariest in Psychiatry

Newsletter

Related Content

What Scares Mental Health Clinicians?

Sorro Encounters Some of the Scariest Topics in the House of Psychiatry

A Story of Crisis Negotiation

Prior Authorizations and (Micro)managed Care

The Negative Impact of the Biodiversity Threat on Mental Health

Latest CME

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Trending on Psychiatric Times

Lecanemab or Lithium? Compare Benefits, Risks, and Dose

FDA Clears Investigational New Drug Application for TNX-102 SL for Treatment of Major Depressive Disorder

Use of TMS in Treatment of Depression, Discussion With Rachel Rohaidy, MD

Glutamatergic Pathways in Major Depressive Disorder: Insights From Juan D. Oms, MD, FAPA

Vagus Nerve Stimulation in Treatment Resistant Depression: New Lines of Thinking